Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for Phase i oncology trial participants - Reply to Fussenich et al.: A new, simple and objective prognostic score for Phase i cancer patients

European Journal of Cancer

Volumn 48, Issue 4, 2012, Pages 594-596

  Olmos, David ^a,b   Ang, Joo Ern ^a,b   Gomez Roca, Carlos ^c   Morales Barrera, Rafael ^d   Vulink, Annelie J ^e   Massard, Christophe ^a,c   Kaye, Stan ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER MORTALITY; CANCER PATIENT; CORRELATION COEFFICIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SODIUM BLOOD LEVEL; STATISTICAL MODEL;

CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; HUMANS; MALE; MEDICAL ONCOLOGY;

EID: 84857039146     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.11.004     Document Type: Letter

References (10)

1. L.M. Fussenich, I.M. Desar, and M.E. Peters A new, simple and objective prognostic score for phase I cancer patients Eur J Cancer 47 8 2011 1152 1160
2. H.T. Arkenau, J. Barriuso, and D. Olmos Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 16 2009 2692 2696
3. H.T. Arkenau, D. Olmos, and J.E. Ang Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience Br J Cancer 98 6 2008 1029 1033 (Pubitemid 351399798)
4. C. Han, J.P. Braybrooke, and G. Deplanque Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents Br J Cancer 89 7 2003 1166 1171 (Pubitemid 37363397)
5. L. Janisch, R. Mick, and R.L. Schilsky Prognostic factors for survival in patients treated in phase I clinical trials Cancer 74 7 1994 1965 1973 (Pubitemid 24301862)
6. N. Penel, M. Vanseymortier, and M.E. Bonneterre Prognostic factors among cancer patients with good performance status screened for phase I trials Invest New Drugs 26 1 2008 53 58
7. Olmos D, A'Hern R, Marsoni S, et al. Patient selection for oncology phase I trials - a multi-institutional study of prognostic factors. J Clin Oncol, in press, doi:10.1200/JCO.2010.34.5074.
8. H.T. Arkenau, D. Olmos, and J.E. Ang 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? Eur J Cancer 44 11 2008 1536 1540
9. D. Olmos, R.D. Baird, and T.A. Yap Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials Clin Cancer Res 17 15 2011 5188 5196
10. N. Penel, J.P. Delord, and M.E. Bonneterre Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics Invest New Drugs 28 1 2010 76 82